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2 
ABSTRACT 26 
Aim: To build a population pharmacokinetic (PopPK) model to characterize 27 
benznidazole (BNZ) pharmacokinetics in adults with chronic Chagas disease.  28 
Methods: Prospective, open-label, single-center clinical trial(EudraCT:2011-29 
002900-34;CINEBENZclinicaltrials.govnumber:NCT01755403), approved by the 30 
local ethics committee. Patients received 2.5mg/kg/12h (Abarax®, Elea 31 
Laboratory, Argentina) for 60 days. Plasma BZN samples were taken at several 32 
times along the study and analyzed by HPLC-UV. The PopPK analysis was 33 
done with NONMEMv.7.3. Demographic and biological data were tested as 34 
covariates. Intraindividual, interoccasion and residual variability were modeled. 35 
Internal and external validations were completed to assess the robustness of 36 
the model. Later on, simulations were performed to generate the BNZ 37 
concentration-time course profile for different dosage regimens. 38 
Results: A total of 358 plasma BZN concentrations from 39 patients were 39 
included in the analysis. A one-compartment-PK-model characterized by 40 
clearance(CL/F) and apparent volume of distribution(V/F) with first order 41 
absorption(Ka) and elimination, adequately described the data (CL/F:1.73 L/h; 42 
V/F:89.6 L; Ka:1.15 h-1). No covariates were found to be significant for CL/F and 43 
V/F. Internal and external validation of the final model showed adequate results. 44 
Data from simulations revealed that a dose of 2.5mg/kg/12h might lead to 45 
overexposure in the most of the patients. A lower dose (2.5mg/kg/24h) was able 46 
to achieve trough BNZ plasma concentrations within the accepted therapeutic 47 
range of 3-6 mg/L. 48 
Conclusion: A population PK model for BNZ in adults with chronic Chagas 49 
disease has been developed. Dosing simulations showed that a BNZ dose of 50 
  
3 
2.5 mg/kg/24h would adequately keep BNZ trough plasma concentrations within 51 
the recommended target range concentrations for the majority of patients.  52 
  
4 
TEXT 53 
Background 54 
Chagas disease is a zoonotic disease endemic in Latin America, particularly 55 
in poor rural areas of Mexico, Central America and South America (1). In recent 56 
last years, the disease and its transmission are not longer limited to endemic 57 
areas and it has turned into an emerging global public health problem mainly 58 
due to migratory flows (2). Its etiological agent is Trypanosoma cruzi, a 59 
hemoflagellate protozoan (family Trypanosomatidae, order Kinetoplastida), 60 
whose life cycle involves obligatory passage through vertebrate hosts 61 
(mammals, including humans) and invertebrate hosts (hematophagous 62 
triatomine bugs) in a series of stages (3). 63 
The disease has two phases: an initial acute phase, which is usually 64 
asymptomatic and a lifelong chronic phase, which in 60 to 70% of patients is 65 
clinically silent, but 30 to 40% of them will develop in years or decades heart 66 
problems (20 to 30%), digestive problems, or a combination of both (10 to 67 
15%). Acute Chagas disease treatment is highly effective whereas the 68 
effectiveness of the antiparasitic treatment to chronically infected patients has 69 
been a subject to controversy for years. Nevertheless, lately the evidence 70 
supporting trypanocidal treatment during chronic stage of the disease has 71 
increased considerably (4–6). 72 
 So far two compounds are available for etiological treatment of Chagas 73 
disease: benznidazole and nifurtimox, though benznidazole (BNZ) is the most 74 
commonly used globally. To date, limited data on benznidazole 75 
pharmacokinetics are available (7–9). These studies showed that BNZ has 76 
good oral bioavailability, an apparent volume of distribution of 0.56 L/kg, and an 77 
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elimination half-life of 12 to 15 h (7, 8). Based on these investigations, the 78 
current recommended dosage of BNZ for the treatment of T. cruzi infection in 79 
humans is 5 mg/kg/d, divided in two doses (2.5 mg/kg/12h) for 60 days. The 80 
trypanocidal concentration of BNZ in-vitro studies ranges from 3 to 6 mg/L (8), 81 
and concentrations close to 20 mg/L had been described to be possibly related 82 
to a higher risk of toxicity, although in a recent study no relationship was found 83 
between the BNZ serum concentration and adverse drug reactions (10).  84 
Giving the limited available data on benznidazole human pharmacokinetics 85 
(7, 8), population pharmacokinetic (popPK) modeling may play an important role 86 
in assessing the effect of demographic and physiological factors on drug 87 
exposure. With the knowledge of the population mean and inter-individual 88 
variability of the PK parameters, it is feasible to: (a) simulate credible responses 89 
to different drug dosing schemes and (b) customize dosage regimens to satisfy 90 
an specific criterion (11, 12).  91 
The main goal of this study was to characterize the pharmacokinetics of 92 
benznidazole in adult patients with Chagas disease, using a model-based 93 
approach, and identify those factors that contribute to its PK variability to 94 
establish new drug dosing schemes. 95 
 96 
Materials and methods 97 
Patients 98 
 The CINEBENZ study is a prospective, open-label, single-center clinical trial 99 
conducted in the Tropical Medicine Unit in the Clinic Hospital of Barcelona and 100 
sponsored by CRESIB (Barcelona Centre for International Health Research). 101 
The protocol was approved by the ethics committee of the Clinic Hospital of 102 
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Barcelona and AEMPS (the Spanish Agency of Medicines and Medical 103 
Devices), was registered in the European Clinical Trials Database (EudraCT: 104 
2011-002900-34) and clinicaltrials.gov website (CINEBENZ clinicaltrials.gov 105 
number: NCT01755403), and was conducted in accordance with the 106 
Declaration of Helsinki and national and institutional standards. Before inclusion 107 
in the study, all patients provided written informed consent. 108 
 Subjects eligible to participate in the study need to meet the inclusion criteria 109 
to be at least 18 years old, diagnosed with Chagas disease by two different T. 110 
cruzi serologic tests and not to have received treatment before. Exclusion 111 
criteria were hypersensitivity to BZN, close follow-up impossibility, 112 
immunodeficiency (HIV, cancer, prolonged corticoid treatments, any other 113 
primary or secondary immunodeficiency), hepatic or renal impairment, 114 
pregnancy or lactation. Enrolled subject received treatment with BNZ 2.5 115 
mg/kg/12h for 8 weeks, with maximum 400mg/day (Abarax®, Elea Laboratory, 116 
Argentina).  117 
  118 
Data 119 
 Demographic characteristics such as age, gender, total body weight, height, 120 
index body mass (total body weight/heigth2) were recorded in the first 121 
evaluation. Clinical laboratory measurements, such as serum creatinine and 122 
creatinine clearance (CLcr), estimated according to the Cockcroft-Gault formula 123 
(13), hematocrit, total serum proteins and total bilirubin were documented in 124 
every visit during treatment. Drug adherence was recorded every follow-up visit 125 
during treatment by drug pill counting by the investigator. 126 
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 Blood BZN samples were taken at different times. They were collected as 127 
follows: (i) 1h; (ii) between 3 and 6h; (iii) and between 6 and 12h after the oral 128 
morning dose (observed by an investigator) on treatment days +1 (first dose) 129 
and +15 (at steady-state conditions). After the last treatment dose, several 130 
samples were also drawn: (i) one point between 3-12h; (ii) another between 12 131 
and 24h; and (iii) an extra sample between 24 and 36h. Additional trough 132 
samples were collected at day +30 and +45, or at unscheduled visits during 133 
routine clinical follow-up, mainly for controlling drug adherence. Time and dose 134 
deviations were recorded and taken into account in the PK analysis.  135 
 All blood samples were centrifuged at 5000 g for 10 min. Plasma was 136 
separated and stored at –40ºC until analysis by high performance liquid 137 
chromatography with ultraviolet-visible detection (HPLC-UV) according to a 138 
previously published methodology developed in our research laboratory (14). 139 
Linearity was found in the range of 1.6-100 mg/L. The analytical error between 140 
replicates was less than 6%. The quantitation and detection limits of the assay 141 
were 1.6 and 0.8 mg/L, respectively. 142 
 143 
Pharmacokinetic modeling 144 
 Non-linear effects modeling was performed using NONMEM v.7.3 (Icon 145 
Development Solutions, USA)(15), following a three step strategy: (a) basic 146 
population model selection, (b) covariate selection, and (c) model validation. 147 
The first-order conditional estimation with interaction (FOCE-I) method was 148 
used for parameter estimation. 149 
 Models of one and two open compartments with first-order absorption and 150 
first-order elimination were evaluated. Interindividual (IIV) and interoccasion 151 
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(IOV) (16) variability were assumed to be log-normally distributed. Regarding 152 
IOV each sampling day was defined as one occasion. 153 
Consider for a generic PK parameter the following model:  154 
P = θP * exp(ηP + κP) 155 
  where θP is the population mean of P (P = CL, V) and ηP and κP are the 156 
random effects capturing the IIV and IOV variability of P, respectively. Additive, 157 
proportional and combined error models were tested for residual variability (RV) 158 
(which comprises measurement and model error) on drug concentrations.  159 
Goodness of fit for a given model was assessed by: (a) changes in the 160 
NONMEM minimum objective function value (OFV): -2log-likelihood; (b) plots of 161 
population and individual Bayesian predicted concentrations vs. observed BNZ 162 
concentrations; and weighted residuals and conditional weighted residuals vs. 163 
observed concentrations and time (17, 18); and (c) changes in the standard 164 
error of parameter estimates (precision). The difference in -2log-likelihood 165 
between two hierarchical models (log-likelihood ratio test) is asymptotically χ2-166 
square distributed with degrees of freedom equal to the difference in number of 167 
model parameters. A significance level of 0.05% and 0.01% denoted a 168 
significant improvement of fit (drop in the OFV by more than 3.841 and 6.64, 169 
respectively) for a one-parameter difference. R v3.1.1 (the R Foundation for 170 
Statistical Computing, Vienna, Austria) and the package Xpose v4.5.0 (19), was 171 
used to guide the model building process. Pearl-speaks-NONMEM (PsN) 172 
v.3.7.3 was used for automation throughout the modeling process (20). 173 
In a second step, all reasonable demographic and biological factors were 174 
tested for inclusion as covariates in the basic population PK model to explain IIV 175 
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variability. They were tested in NONMEM by using “scm” approach. Continuous 176 
covariates were generally assessed as follows: 177 
 Pj = PPOP * (Covj / CovMEAN) θCOV 178 
where Pj is the PK parameter for the jth patient and a given covariate value, 179 
PPOP is the typical value of a PK parameter corresponding to the mean value of 180 
the covariate of interest in the population, Covj is the value of that covariate for 181 
the jth patient, CovMEAN is the mean of the covariate in the population and θCOV 182 
represents the scaling factor for the influence of that covariate. Categorical 183 
variables were included in the model as expressed below: 184 
 Pj = PPOP + θCOV (1 – Covi) 185 
where Pj is the PK parameter for the jth patient, Covi is a numeric index value 186 
(in that case: 1 for the reference category or 0 for the comparative category), 187 
PPOP is the typical value of a PK parameter for the reference covariate values 188 
(ie: Covi equals 1) and θCOV is the multiplicative factor for the influence of this 189 
covariate on the PK parameter. 190 
Covariates were first entered one by one into the population model and then 191 
by the cumulative forward inclusion/backward elimination procedures. Each 192 
covariate investigated in NONMEM was retained if it led to a significant 193 
improved fit. Improvements to the model were evaluated by: (a) biological 194 
plausibility of the covariate, (b) graphical displays based on the agreement 195 
between the observed (OBS) and predicted drug concentrations, (c) the 196 
uniformity of the distribution of the residuals, and (d) the log-likelihood ratio test 197 
between two-nested models. Covariates were kept in the model if they yielded a 198 
significant level of 5% (reduction in the log-likelihood ratio test of 3.841 points). 199 
A significant level of 1% (increase in the log-likelihood ratio test of 6.635 points) 200 
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was employed during the backward elimination step. A decrease of at least 10% 201 
in IIV associated with a specific pharmacokinetic parameter was considered 202 
clinically relevant for the inclusion of that specific covariate. The extent of 203 
Bayesian shrinkage in the PK parameters was evaluated for each parameter in 204 
the final model (21). 205 
 206 
Model evaluation 207 
 The internal validation of the PK model was assessed by graphical and 208 
statistical methods, including visual predictive checks (vpc) (22). Bootstrap 209 
resampling technique (with replacement) was used to build confidence intervals 210 
(CIs) of pharmacokinetic parameters to assess their stability and evaluate the 211 
robustness of the final model (23). It was performed in PsN v.3.7.3 (University 212 
of Uppsala, Sweden) (20). The final model was fitted to the replicate data sets 213 
(200 data sets), and parameter estimates for each of them were obtained. The 214 
mean values (and the lower and upper limits of the 95% CI) of the parameters 215 
obtained were compared with those estimated from the original data. 216 
The external predictive performance of the PK model was assessed by 217 
analyzing data from new individuals (validation data set) treated with BNZ in 218 
similar conditions to the study population (index data set) (24). Individual 219 
predicted BNZ concentrations for all sampling times were obtained by Bayesian 220 
estimation (“posthoc” subroutine of NONMEM without the estimation step) 221 
setting population PK parameter values (mean PK parameters, interindividual 222 
and residual variability) to population values previously obtained in the index 223 
data set. The performance of the Bayesian analysis was evaluated by 224 
comparison of the observed (OBS) concentrations with the population predicted 225 
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(PRED) and individual predicted (IPRED) concentration values. Bias and 226 
precision were calculated and expressed in terms of percentage prediction error 227 
(IPE% and PPE% for IPRED and PRED, respectively) and absolute percentage 228 
prediction error (IAPE% and PAPE% for IPRED and PRED, respectively), (25). 229 
 230 
Dosage regimen simulations: 231 
 Monte Carlo simulations (1000 simulations) were performed using the final 232 
model for BNZ to investigate the presumed steady-state drug concentrations for 233 
new dosing regimens. Following the presumption that the effectiveness of BZN 234 
depends on sustaining a concentration within the trypanocidal range (3-6 mg/L) 235 
(8), the recommended dose regimen of 2.5 mg/kg/12h and a once daily dose of 236 
2.5 mg/kg and 5 mg/kg were evaluated.  237 
 However, considering the recent finding of Bustamante et al. (26) that T. 238 
cruzi infection can be cured (in mice) using 13 doses of BNZ given at 5 days 239 
intervals, and the knowledge of the T. cruzi life cycle duration (1, 26) a dose 240 
regimen of 5 mg/kg of BZN 5 days apart was also tested by simulating 1000 241 
patients from our final population PK model.  242 
 243 
Influence of body weight on dosage: 244 
 Based on the theory-based PK modeling approach, some relationships may 245 
be included in the popPK model even without being statistically significant. In 246 
this context, the inclusion of allometric scaling on the PK parameters could help 247 
to have an idea of the connection between body size and drug PK; particularly, 248 
the influence of body weight on optimal dosing. BNZ is dosed on kilograms 249 
basis and thus, this may have a certain impact on drug exposure. With the 250 
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intention to understand the influence of total body weight on BNZ PK, we 251 
decided to include this effect in the model to assess the fraction of patients’ 252 
over- and underexposed at extreme weights; 43 Kg and 100 Kg. These values 253 
correspond to the minimum and maximum total body weight in our cohort of 254 
patients.  255 
 Hence, 1000 additional simulations were done using a new popPK model 256 
(WT-popPK model) including the allometric scalling on the PK parameters, as 257 
follows:  258 
      CLi/F = TVCL* (WTi/WTmean)**0.75      ;      Vi/F = TVV * (WTi/WTmean)**1 259 
where: CLi/F and Vi/F are the individual total BNZ clearance and apparent 260 
volume of distribution for the ith individual, TVCL and TVV are the “typical” 261 
population values of the drug clearance and apparent volume of distribution, 262 
WTi is the weight of the ith individual and WTmean is the average weight of all 263 
patients included in the study. The allometric exponents were fixed to the values 264 
obtained from the literature (27, 28). 265 
 266 
Statistical analysis: 267 
 Statistical analysis was performed using S-Plus 6.1 (S-Plus 6.1 for Windows 268 
Insightful Corporation, Seattle WA. Insightful Corporation, 2002). Mean, median, 269 
standard deviations (SD), 90% confidence intervals [90% CI] and quartiles (q) 270 
were calculated for continuous variables. Student t-test was used for comparing 271 
normally distributed variables, U-Mann Whitney test was used for comparing 272 
non-normally distributed variables. 273 
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 Results are expressed as absolute and relative frequencies for categorical 274 
variables and Chi-square test was used for comparing them. The significance 275 
level for all the analyses was defined as p<0.05. 276 
 277 
RESULTS 278 
 279 
Subjects and samples: 280 
Fifty-two subjects met the enrolment criteria and signed the informed 281 
consent. One subject withdrew the consent before treatment was started. Two 282 
subjects were excluded from the PK analysis due to early treatment 283 
discontinuation because of adverse reactions. Eventually 49 subject’s samples 284 
were analysed. The majority of patients were from Bolivia (96%), women (71%) 285 
and the median age was 36 (range from 19 to 55).  286 
 287 
Data from 39 subjects were use in the model construction (Table 1: index 288 
data set) and 10 for validation (Table 1: validation data set). A total of 358 289 
plasma BZN concentrations ranging from 0.56 to 28.94 mg/L, were used during 290 
the analysis (index data set). On average, 9.1 samples were collected per 291 
patient during the whole study. Patients’ age and body weight (index data set) 292 
ranged from 19 to 55 (mean: 37.15 years) and 43 to 105 (mean: 70.55 kg), 293 
respectively. Mean values (± SD) in this group were: CLcr: 124.4 ± 25.1 mL/min; 294 
hematocrit: 0.40 ± 0.04%; total serum proteins: 72.9 ± 4.2 mg/dL. The median 295 
global adherence (index data set + validation data set) was 99.2% with only two 296 
cases with adherence lower than 85%. 297 
 298 
 299 
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Population pharmacokinetic model: 300 
 The pharmacokinetics of BNZ was best described by a one-compartment 301 
open linear model with first order absorption and first order elimination, typified 302 
by apparent clearance (CL/F), apparent volume of distribution (V/F) and 303 
population absorption rate constant (Ka). A second distribution compartment did 304 
not improve the model fit. BNZ was administered as an oral tablet and the 305 
bioavailability of the drug could not be estimated. Hence, the model estimates 306 
are the values of apparent clearance (CL/F) and volume of distribution (V/F), 307 
where F represents oral bioavailability. The available data did not support the 308 
estimation of Ka and thus it was set to a fixed value obtained from the literature 309 
(8). Interindividual variability (IIV) was incorporated in CL/F and V/F. 310 
Interoccasion variability (IOV) in CL/F significantly reduced the OFV ratio test 311 
(∆ 97 points; P > 0.001). Residual variability (RV) was characterized by a 312 
combined error model with a proportional part of 19.1% (expressed as 313 
coefficient of variation [CV%]) and an additive part of 0.57 mg/L (expressed as 314 
standard deviation [SD]).  315 
During covariate model selection, the effect of age, gender, total body 316 
weight, index body mass, CLcr, total serum proteins and total bilirubin were 317 
tested on relevant pharmacokinetic parameters (CL/F and V/F). The results 318 
showed that none of the covariates (age, gender, total body weight, index body 319 
mass, total bilirubin, total serum proteins, hematocrit and CLcr) significantly 320 
influenced BNZ CL/F (reduction of the NONMEM objective function value 321 
(p<0.05)). Inclusion of covariates in V/F failed to cause a significant drop in the 322 
OFV ratio test as well.  323 
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An overview of goodness-of-fit-plots for the final PK model is given in Fig. 1. 324 
A good accordance between observed and population/individual predicted 325 
concentrations is observed. Residual error plots showed no systematic 326 
deviation over time (Fig 1). The mean of the CWRES was 0.085, close to zero, 327 
indicating the ability of the estimation method to fit the model to the data. The 328 
model parameters had reasonably levels of η-shrinkage for CL/F (13.1%) and 329 
V/F (34.7%). The magnitude of the ε-shrinkage was 27.7%. 330 
An overview of the pharmacokinetic parameter estimates from the final 331 
population PK model is presented in Table 2. 332 
 333 
Model validation: 334 
 As shown in Fig. 2, results from the visual predictive check showed that 335 
practically all observations dropped into the 95% confidence intervals (CI). The 336 
statistical distributions of the parameter estimates obtained from the bootstrap 337 
analysis are shown in Table 2. Median values of the parameter estimated from 338 
the bootstrap are in good agreement with the NONMEM point estimates, and 339 
the 95% CIs were reasonably narrow, demonstrating satisfactory precision. 340 
Visual and numerical predictive checks demonstrated good predictive 341 
performance of the final pharmacokinetic model. 342 
 Regarding the predictive performance of the model, the validation data set 343 
included 10 new patients whose demographic and clinical characteristics are 344 
displayed in Table 1. A total of 96 plasma BZN concentrations ranging from 345 
0.57 – 13.21 mg/L, were used for external validation of the full model. On 346 
average, 9.6 samples were collected per patient. Patients’ age and body weight 347 
ranged from 26 to 52 (mean: 38.8 years) and 51 to 91 (mean: 68.4 kg), 348 
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respectively. Mean values (± SD) in this group were: CLcr: 125.7 ± 23.1 mL/min; 349 
hematocrit: 0.38 ± 0.03%; total serum proteins: 70.5 ± 1.8 mg/dL. Median bias 350 
and precision for the MAP Bayesian estimates (IPRED) resulted in 0.76% and 351 
9.04%, respectively, much better than those values obtained from the 352 
population PK-model based estimates (PRED), which were –32.73% and 353 
36.19%, respectively (Fig. 3). 354 
 355 
Dosage regimen simulation at steady state conditions:   356 
 Results from simulations are displayed in Table 3. The usual dose regimen 357 
of 2.5 mg/kg/12h, for an average patient of 70 kg of weight, would be enough to 358 
attain the target trypanocidal concentration during the whole inter-dose interval 359 
(12 hours) in almost all treated subjects (95% of the patients; quartile 5th: q5: 360 
3.02 mg/L at 10h), since the simulated trough median [90% confidence interval: 361 
CI] at steady-state resulted to be 7.53 [2.81 – 17.48] mg/L.     362 
 Simulations considering other dose regimens such as (a) 2.5 mg/kg/day 363 
q.d., (b) 5 mg/kg/day q.d. and (c) an extended dosing interval of 5 mg/kg of BZN 364 
5 days apart were also done. The median [90% CI] trough BNZ plasma 365 
concentrations at the last day of treatment (steady-state conditions) from 1000 366 
simulated profiles are shown in Table 3. For an average patient of 70 kg, the 367 
results indicated that once daily dose regimens: 2.5 mg/kg/day q.d. and 5 368 
mg/kg/day q.d. were able to attain the target trypanocidal concentration during 369 
the whole inter-dose interval of 24 hours. In contrast, for the extended dosing 370 
interval of 5 mg/kg of BZN 5 days apart the drug levels fell below the minimum 371 
trypanocidal level after 48 hours (median [90% CI]: 2.83 [0.54-6.36] mg/L). With 372 
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this extended regimen, the median [90% CI] peak BNZ concentrations 2h after 373 
dose were 7.49 [2.81-20.36] mg/L. 374 
 375 
Influence of body weight on dosage: 376 
 The final popPK model including the allometric relationship between body 377 
weight and PK parameters (WT-popPK) did not improve the fit. The population 378 
PK estimates were very similar to the original final popPK model (without 379 
considering weight as an influential covariate). In the WT-popPK model the final 380 
estimates of fixed effect parameters were: CL/F=  1.75 L/h, V/F = 95.3 L, 381 
respectively. Ka was fixed to 1.15. Lognormal IIV in CL/F and V/F resulted in 382 
values of 34.1% and 77.3%, respectively. Interoccasion variability was only 383 
retained for CL/F (30%), as in the original model. 384 
 Results of simulations after considering the influence of body weight on BNZ 385 
dosing and drug exposure are presented in Table 3. 386 
 387 
DISCUSSION 388 
 The most widely available drug for treating Chagas disease is benznidazole, 389 
but little information exists on its pharmacokinetics. Recently a study on 390 
population PK of benznidazole in children was published (29) but to our 391 
knowledge, the present population PK study is the first to examine benznidazole 392 
plasma concentrations in adult subjects with Chagas’ disease.  393 
In this study we used NONMEM v.7.3 (15) to characterize the PK of the drug 394 
and to investigate quantitative relationships between the pharmacokinetic 395 
parameters and physiological and/or demographic features, in subjects with 396 
Chagas disease treated with benznidazole. The data collected in this study was 397 
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best described by an open one-compartment PK model with first-order 398 
absorption and elimination, characterized by CL/F, V/F and Ka, which is in 399 
accordance with previous data (7, 8). The population estimates for CL/F and 400 
V/F were 1.73 L/h and 89.6 L, respectively; again in line with previously 401 
published results. Interindividual variability (IIV) was incorporated in CL/F and 402 
V/F and interoccasion variability in CL/F significantly reduced the OFV (P = 403 
0.01). Our work showed a high interindividual variability for PK parameters, 42% 404 
in CL/F and 39.3% in V/F [CV%]. However, neither CL/F nor V/F was 405 
significantly influenced by the studied demographic or physiopathological 406 
factors. Goodness-of-fit plots and simulation-based diagnostics showed that the 407 
model described the data adequately. 408 
 Previous BZN PK studies were conducted in healthy volunteers (7) or 409 
patients with chronic Chagas disease (8) and have been analyzed (posthoc 410 
analysis) on a population approach basis by Altchech et al. (29). In these 411 
studies, combined data from healthy (single dose) and patients (multiple doses) 412 
led to a value of CL/F of 0.0301 L/h/kg (2.17 L/h for a patient of 70 kg) and a 413 
typical half-life value of 12.77 h. In the present study, performed at steady-state 414 
conditions in 39 adults with chronic Chagas disease, the estimated terminal 415 
drug half-life was about 36 hours, which is quite longer than the previous 416 
estimates. We presume this might be related to the different characteristics of 417 
the study populations, mainly patient condition vs. healthy and adults vs. 418 
pediatrics.   419 
 Regarding the inclusion of IOV on CL/F after repeated oral BNZ, and taking 420 
into account the excellent adherence to treatment seen in our cohort of patients 421 
all along the study, with a mean (± SD) drug adherence of 98.12 ± 7.53%), it is 422 
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possible to hypothesize that variability might be attributed to differences either 423 
in CL or in bioavailability (F). Unfortunately, intravenous BNZ is not available in 424 
the market and hence it is not possible to use it as a reference form to estimate 425 
the “true clearance: CL”. Thus, it was not feasible to discriminate in our model if 426 
IOV was related to CL or F since after oral drug administration CL and systemic 427 
availability are confounded (16).  428 
A major goal of population PK studies is to identify those covariates which 429 
explain the variation in the between-patient variance component (30). However, 430 
none of the covariates tested in this study showed a significant impact on oral 431 
BNZ pharmacokinetics in our sample. Besides, another valuable feature of 432 
population PK studies is the opportunity to perform Monte Carlo simulations 433 
(11). This is a very powerful method used to forecast therapeutic outcomes and 434 
design adequate dosing regimens (effective and safe) (12). Therefore, we 435 
applied this methodology to theoretically determine the suitability of several 436 
potential BNZ dosage regimens which could be further tested in clinical trials 437 
(31). However, before carrying out any simulation to assist us in selecting an 438 
optimal initial dosage regimen, it should be previously established that the 439 
described population PK model is predictive (24). External validation was 440 
conducted by assessing the ability of the population model to predict 441 
concentrations in a separate group of 10 patients with chronic Chagas disease. 442 
The model was evaluated by means of bias and precision showing mean values 443 
within acceptable limits (0.76% and 9.04%, respectively) and supporting the 444 
validity and the further utility of this population PK model. 445 
 To date, no other pharmacokinetics/pharmacodynamics relationship or 446 
target exposure values other than keeping BNZ trough concentrations within or 447 
  
20 
above the in vitro trypanosomicidal range (3-6 mg/L) (8) have been established 448 
for optimizing treatment of Chagas disease. However, it must be noted in that in 449 
several studies in the last 25 years (32–35) have shown that in many cases 450 
there is no correlation between the in vitro susceptibility of a given T. cruzi strain 451 
to benznidazole or nifurtimox and the efficacy of antiparasitic treatment with 452 
these drugs in experimental animals or human patients. This lack of correlation 453 
is explained by the multiple physicochemical and biochemical barriers to access 454 
of any drug to their potential cellular targets in an intact organism, a fact that 455 
may contribute to the known variability of the outcome of etiological treatment 456 
(36).  457 
 Data from the original study (popPK) showed that the standard 5 mg/kg/day 458 
of BZN divided in two doses (2.5 mg/kg/12h) lead to a median [90%CI] trough 459 
BNZ concentration of 7.53 [2.81 - 17.48] mg/L, for an average patient of 70 kg. 460 
As expected, for 2.5 mg/kg/12h, the simulated trough concentration of BNZ, 461 
were below 3 mg/L at 12h in only 5% of patients, consistent with the observed 462 
data in this study. Looking deeper into our dataset we noted that only 5.4% of 463 
the observed (real) BNZ trough concentrations were below 3 mg/L, 20% of them 464 
were within the optimal range (3-6 mg/L) but the most of them, 74.54% above 6 465 
mg/L. These results support the views of other authors (26, 29), which 466 
suggested that standard treatment protocols using BNZ might be significantly 467 
overdosing patients and therefore studies with lower doses in adults might be 468 
justified. 469 
Therefore, by means of Monte Carlo simulations, a new 50% reduced total 470 
dose regimen of 2.5 mg/kg once daily was tested. Results from this test showed 471 
that this new proposed dose could keep median BNZ concentrations above 3 472 
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mg/L for the whole interval of 24h. It should be noted that for this dose regimen 473 
sub-therapeutic trough concentrations (< 3 mg/L) were reached at 18 hours of 474 
BNZ administration in only 15% of patients. As regards to the once daily dose 475 
regimen of 5 mg/kg/24h, median trough concentrations were always above the 476 
upper limit of the therapeutic range (> 6 mg/L) and only in 4-5% of cases, BNZ 477 
concentrations would feel below 3 mg/L during the last 4 hours of a dose 478 
regimen of 24h. With this dosing regimen the most distressing point would be 479 
the BNZ concentrations achieved at earlier times after drug administration 480 
(median Cmax [90% CI: 7.49 [2.87-20.36] mg/L just 2-3 hours after dose, since in 481 
5% of patients it could reach values close to the toxic level of 20 mg/L. Even 482 
though our previous work (37) showed that BNZ concentrations might not be 483 
related to the appearance of serious drug effects, we believe such high drug 484 
concentrations are neither desirable nor needed in patients with Chagas 485 
disease. Finally, simulations for 5 mg/kg/5 days showed median trough 486 
concentrations far below the recommended target of 3 mg/L (Table 3). As 487 
stated before, we chose this dose schedule by imitating the dosage regimen 488 
used by Bustamante et al. (26) in their study in mice. However, the 489 
effectiveness of these regimens in which minimum BNZ concentrations remain 490 
below the suggested goal are still controversial. They are based on the fact that 491 
drug efficacy would be related to the maximum BNZ concentration (Cmax). Up to 492 
now, this assumption has not been proved in humans and making it difficult to 493 
recommend these extended intervals (> 24 h) in Chagas’ treatment.  494 
 In our final popPK model, total body weight (WT) did not find a significant 495 
influence on any PK parameter. In order to investigate a possible weakness due 496 
to this fact, we conducted additional simulations taking into account the 497 
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theoretical relationship between WT and PK, based on the allometric scaling 498 
described in many references in the literature (27,28). Results from simulations 499 
show that the usual dose regimen of 2.5 mg/kg/12h would allow achieving the 500 
target of 3 mg/L during the whole inter-dose interval in almost all of the treated 501 
subjects. Taking into account the influence of total body weight on the 502 
administered dose, the simulated trough BNZ median [90% CI] concentration at 503 
steady-state resulted to be 7.73 [2.88-17.61] mg/L and 10.05 [4.06-23.33] mg/L 504 
for an average patient of 43 kg and 100 kg ot total body weight, respectively 505 
(Table 3). However, probably more important is the fraction of patients over- 506 
and underexposed to BNZ, based on the weight-base dosing, since these are 507 
the patient on risk. These data are displayed in Table 3. Simulations with 2.5 508 
mg/kg/12h and 5 mg/kg/24h of BNZ showed that the percentage of patients with 509 
trough BNZ concentrations higher than 6 mg/L was between 70-80%. No 510 
significant differences within groups of different total body weight were seen. 511 
These high concentrations are probably excessive and we might consider they 512 
could be toxic (in 5% of patients; upper limit of the CI higher or equal to 20 513 
mg/L). From this point of view, a reduction in the total BNZ daily dose might be 514 
considered. The fraction of overexposed patients decreased to 25-34% for a 515 
dosage regimen of 2.5 mg/kg/24h with no risk of achieving toxic concentrations. 516 
Nonetheless, with this dose regimen, the risk of BNZ under-exposition (median 517 
trough concentrations below 3 mg/L at 24h) increased up to around 30% of 518 
patients. Interestingly, and regardless of the total body weight, only 15% of 519 
patients would show sub-therapeutic trough BNZ concentrations at 18 hours of 520 
BNZ administration. Total body weight had no impact on the fraction of patients 521 
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under-exposed since no significant differences were seen between groups 522 
(p>0.05) (Fig.4). 523 
 A potential limitation of any population PK study could be the lack of 524 
treatment adherence in some patients. Nonetheless, this limitation does not 525 
affect our results because the median global adherence in our cohort of patients 526 
was 99.2%, with only two cases with values lower than 85%. Another drawback 527 
to consider is the impossibility to determine the absolute BNZ bioavailability and 528 
the influence of the IOV on it since there is no intravenous formulation to use as 529 
a comparator to the oral one.  530 
The current study represents a first step toward developing optimal oral BNZ 531 
dosing schedules for the treatment of Chagas disease patients on the basis of a 532 
better knowledge of BNZ pharmacokinetics in adults. 533 
 534 
In conclusion, this is the first population PK study in adults demonstrating 535 
that the standard doses of oral BNZ (2.5 mg/kg/12h) may be significantly 536 
overdosing patients. In addition, the results from this study might assist the 537 
optimization of BNZ dosing regimens and highlight the rational of proposing a 538 
lower BNZ dose (2.5 mg/kg/24h). Additional clinical trials in adults with this 539 
lower BNZ dose, looking for safety and mainly efficacy, might be warranted 540 
before recommending its use in Chagas disease treatment. 541 
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Table 1: Blood samples and patients’ characteristics for both groups of patients: 664 
the index data set and the validation data set. CLcr: creatinine clearance 665 
(mL/min).  666 
 Index data set Validation data set 
Total plasma samples 358 96 
Plasma concentrations range (mg/L) 0.56 – 28.9 0.57 – 13.21 
No. (females/males) 39 (26/13) 10 (9/1) 
Plasma samples/subject 9.1 9.6 
Age (years) 37.1 ± 7.5 38.8 ± 8.6 
Weight (kg) 70.5 ± 14.5 68.4 ± 11.3 
Body mass index  (kg/m2) 27.8 ± 4.4 26.9 ± 4.4 
Hematocrit (%) 0.40 ± 0.04 0.38 ± 0.03 
Serum creatinine (mg/dL) 0.70 ± 0.14 0.67 ± 0.10 
CLcr (mL/min) 124.4 ± 25.1 125.7 ± 23.1 
Total serum proteins (mg/dL) 72.9 ± 4.2 70.5 ± 1.8 
Total bilirubin (mg/dL)  0.6 ± 0.2 0.6 ± 0.3 
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Table 2: Benznidazole population pharmacokinetic parameter (PPK) estimates 667 
for the base and final models and bootstrap results for the final model 668 
Parameter 
Base/final PPK 
model estimate  
Mean [(95% CI) bootstrap results(a)] 
Pharmacokinetic parameters 
CL/F (L/h) 1.73 1.73 [ 1.54 – 1.92 ] 
V/F (L)  89.6  92.54 [ 45.56 – 133.64] 
Ka (h-1) 1.15 FIX ---- 
Interindividual (IIV) variability in(b): 
CL/F 33.4 33.1 [17.3 – 44.0] 
V/F 68.8 72.3 [25 – 94.2] 
Interoccasion (IOV)variability in(b): 
CL/F 29.5 29.9 [20.4 – 36.4] 
Residual variability (RV): 
σ21 (mg/L) 0.57 ± 0.19 0.56 [0.12 – 1.27] 
σ22 (CV%) 19.53 17.1 [24.1 –  57.1] 
σ21: standard deviation of additive component of residual variability; σ22: variance of proportional 669 
component of residual variability. 670 
(a) Derived from 200 successful bootstrap sample runs. (b) Estimates of 671 
interindividual/interoccasion variability are expressed as coefficient of variation of variance 672 
values (CVω2). 673 
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Table 3: Trough BNZ plasma concentrations in mg/L (expressed as median 674 
[90% CI]) at steady-state conditions, and percentage of patients with trough 675 
BNZ concentration > 6 mg/L or < 3 mg/L, resulting after simulating 1000 PK 676 
profiles for different dosing schemes and total body weight.  677 
 678 
  43 kg 70 kg 100 kg 
Median 
[90%CI] 
7.73 
[2.88-17.61] 
7.53 
[2.81-17.48] 
10.05 
[4.06-23.33] 
[BNZ] >6 mg/L 
at 12h (%) 69.5 67.7 81.8 2.5 mg/kg/12h 
[BNZ] <3 mg/L 
at 12h (%) 5.3 5.5 1.6 
Median 
[90%CI] 
3.78 
[0.88-9.51] 
4.27 
[1.20-10.19] 
4.64 
[1.52-12.1] 
[BNZ] >6 mg/L 
at 24h (%) 22.5 27.5 34.2 2.5 mg/kg/24h 
[BNZ] <3 mg/L 
at 24h (%) 33.6 25.5 23.5 
Median 
[90%CI] 
7.87 
[2.20-19.07] 
9.59 
[2.90-23.81] 
9.32 
[2.81-22.90] 
[BNZ] >6 mg/L 
at 24h (%) 70.2 80 79.2 5 mg/kg/24h 
[BNZ] <3 mg/L 
at 24h (%) 7.8 4.5 5.8 
Median 
[90%CI] 
0.61 
[0.08-2.34] 
0.69 
[0.067-2.61] 
0.69 
[0.062-2.80] 
[BNZ] >6 mg/L 
at 168h (%) 0 0 0.4 5 mg/kg/5days 
[BNZ] <3 mg/L 
at 168h (%) 97.7 96.6 94.2 
 679 
[BNZ]: BNZ concentration 680 
 681 
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Legend for figures 682 
 683 
Fig. 1: Goodness of fit plots for the final population PK model. Left upper panel: 684 
plot of population predictions (PRED) vs. observed BNZ concentrations (OBS); 685 
Right upper panel: plot of individual population predictions (IPRED) vs. OBS; 686 
left lower panel: individual weighted population residuals (IWRES) vs. IPRED; 687 
right lower panel: conditional weighted residuals (CWRES) vs. time. Black 688 
dashed line: line of identity (upper panels) or target line (lower panels); red thick 689 
line: line indicating the general data trend. Concentrations (OBS, PRED and 690 
IPRED) are in mg/L; time is in hours. 691 
 692 
Fig. 2: Visual predictive check (VPC). Comparison between the 5th, 95th (dashed 693 
lines) and 50th (full line) percentiles obtained from 1000 simulations and the 694 
BNZ observed plasma concentrations (open circles) for adults Chagas patients. 695 
 696 
Fig. 3: Box-plots of percentage error (PE) and absolute percentage error (APE) 697 
of the validation data set as a measure of bias and precision, respectively. 698 
Ordinate: in percentage. The white band in each error box marks the 50th 699 
percentile (dashed line); the box boundaries are at the 25th and 75th percentiles, 700 
and the limits of the whiskers are at the 10th and 90th percentiles. Other 701 
horizontal lines are “outliers”, i.e. values outside the 10-90-percentile range. 702 
IPE: Percentage error for the individual predictions; PPE: Percentage error for 703 
the population predictions. IAPE: Absolute percentage error for the individual 704 
predictions; PAPE: Absolute percentage error for the population predictions. 705 
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Fig. 4: Median BNZ concentrations vs. time at steady state (from 1000 706 
simulated profiles) for a dose regimen of 2.5 mg/kg/24h and different total body 707 
weight: 43 Kg (dashed line), 70 Kg (solid line) and 100 Kg (dotted line). Y-axis: 708 
BNZ conc (mg/L); x-axis: time (h). Trypanosomicidal range concentrations (3-6 709 
mg/L). Median trough at 24h for 43 Kg (dashed line): 3.78 mg/L, 70 Kg (solid 710 
line): 4.27 mg/L and 100 Kg (dotted line): 4.64 mg/L (p>0.05).    711 
  712 
